b7-h3 car t cells
Desmoplastic Small Round Cell Tumor
Explore 10 assets in Desmoplastic Small Round Cell Tumor →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04897321CT.gov B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Desmoplastic Small Round Cell Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| b7-h3 car t cells (this asset) | St. Jude Children's Research Hospital | P1 | CC · 43 |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | B |
| Fludarabine | St. Jude Children's Research Hospital | P2 | B |
| Imatinib | National Cancer Institute (NCI) | P2 | B |
| Etoposide | M.D. Anderson Cancer Center | P2 | CCC |
| Melphalan | M.D. Anderson Cancer Center | P2 | CCC |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | CCC |
| Thiotepa | M.D. Anderson Cancer Center | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P1 | CCC |
+18 more in the Desmoplastic Small Round Cell Tumor cohort
Other indications for b7-h3 car t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Wilms Tumor | — | P1 | CC · 43 |
| Adrenal Cortex Carcinoma | — | P1 | CC · 43 |
| Malignant Germ Cell Tumor | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. b7-h3 car t cells in Desmoplastic Small Round Cell Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/b7-h3-car-t-cells-desmoplastic-small-round-cell-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →